The involvement of Aurora-A and p53 in oxaliplatin-resistant colon cancer cells

被引：1

作者：

Chen, Mei-Chih ^{[1
,2
]}

Yang, Bing-Ze ^{[3
]}

Kuo, Wei-Wen ^{[4
]}

Wu, Shih-Hsin ^{[3
]}

Wang, Tso-Fu ^{[5
]}

Yeh, Yu-Lan ^{[6
]}

Chen, Ming-Cheng ^{[7
,8
]}

Huang, Chih-Yang ^{[3
,9
,10
,11
,12
,13
]}

机构：

[1] China Med Univ Hosp, Translat Cell Therapy Ctr, Dept Med Res, Taichung, Taiwan

[2] Asia Univ, Dept Nursing, Taichung, Taiwan

[3] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan

[4] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan

[5] Dept Hematol & Oncol, Hualien, Taiwan

[6] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan

[7] Taichung Vet Gen Hosp, Dept Surg, Div Colorectal Surg, Taichung, Taiwan

[8] Natl Yang Ming Chiao Tung Univ, Coll Med, Taipei, Taiwan

[9] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Cardiovasc & Mitochondrial Related Dis Res Ctr, Hualien, Taiwan

[10] Tzu Chi Univ Sci & Technol, Buddhist Tzu Chi Med Fdn, Holist Educ Ctr, Dept Sci, Hualien, Taiwan

[11] China Med Univ Hosp, China Med Univ, Dept Med Res, Taichung, Taiwan

[12] Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan

[13] Hualien Tzu Chi Hosp, Cardiovasc & Mitochondria Related Dis Res Ctr, Hualien 970, Taiwan

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2023年 / 124卷 / 04期

关键词：

Aurora-A; colon cancer; drug resistance; oxaliplatin; p53; OVARIAN-CANCER; BREAST-CANCER; KINASE; OVEREXPRESSION; PHOSPHORYLATION; CHECKPOINT; CHEMORESISTANCE; AMPLIFICATION; COMBINATION; LEUCOVORIN;

D O I：

10.1002/jcb.30394

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Resistance to chemotherapy is the deadlock in cancer treatment. In this study, we used wild-type LOVO (LOVOWT), a human colon cancer cell line, and the oxaliplatin-resistant sub-clone LOVOOR cells to investigate the molecular mechanisms of the development of drug resistance in colon cancer. Compared with LOVOWT cells, LOVOOR cells had a high proliferation capacity and a high percentage on the G2/M phase. The expression and activation of Aurora-A, a critical kinase in G2/M phase, were higher in LOVOOR cells than in LOVOWT cells. The results from immunofluorescence indicated an irregular distribution of Aurora-A in LOVOOR cells. To evaluate the importance of Aurora-A in oxaliplatin-resistant property of LOVOOR cells, overexpression of Aurora-A in LOVOWT cells and otherwise knockdown of Aurora-A in LOVOOR cells were performed and followed by administration of oxaliplatin. The results indicated that Aurora-A might contribute to the resistance of LOVOOR cells to oxaliplatin treatment by depressing p53 signaling. The specific findings in this study provide a possibility that targeting Aurora-A might be a solution for patients who have failed oxaliplatin treatment.

引用

页码：619 / 632

页数：14

共 43 条

[1] Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Alcaraz-Sanabria, Ana
Nieto-Jimenez, Cristina
Corrales-Sanchez, Veronica
Serrano-Oviedo, Leticia
Andres-Pretel, Fernando
Carlos Montero, Juan
Burgos, Miguel
Llopis, Juan
Maria Galan-Moya, Eva
Pandiella, Atanasio
Ocana, Alberto
[J]. MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) : 2552 - 2562
[2] AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol
Anand, S
Penrhyn-Lowe, S
Venkitaraman, AR
[J]. CANCER CELL, 2003, 3 (01) : 51 - 62
[3] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
Andre, T
Boni, C
Mounedji-Boudiaf, L
Navarro, M
Tabernero, J
Hickish, T
Topham, C
Zaninelli, M
Clingan, P
Bridgewater, J
Tabah-Fisch, I
de Gramont, A
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
[4] Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers
Aradottir, Margret
Reynisdottir, Sigridur T.
Stefansson, Olafur A.
Jonasson, Jon G.
Sverrisdottir, Asgerdur
Tryggvadottir, Laufey
Eyfjord, Jorunn E.
Bodvarsdottir, Sigridur K.
[J]. JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2015, 1 (01) : 33 - 40
[5] A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Beltran, Himisha
Oromendia, Clara
Danila, Daniel C.
Montgomery, Bruce
Hoimes, Christopher
Szmulewitz, Russell Z.
Vaishampayan, Ulka
Armstrong, Andrew J.
Stein, Mark
Pinski, Jacek
Mosquera, Juan M.
Sailer, Verena
Bareja, Rohan
Romanel, Alessandro
Gumpeni, Naveen
Sboner, Andrea
Dardenne, Etienne
Puca, Loredana
Prandi, Davide
Rubin, Mark A.
Scher, Howard I.
Rickman, David S.
Demichelis, Francesca
Nanus, David M.
Ballman, Karla V.
Tagawa, Scott T.
[J]. CLINICAL CANCER RESEARCH, 2019, 25 (01) : 43 - 51
[6] Adjuvant chemotherapy of stage III colon cancer
Benson, AB
[J]. SEMINARS IN ONCOLOGY, 2005, 32 (06) : S74 - S77
[7] [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[8] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
Cavanna, Luigi
Artioli, Fabrizio
Codignola, Claudio
Lazzaro, Antonio
Rizzi, Anna
Gamboni, Alessandro
Rota, Luigina
Rodino, Carmelina
Boni, Fabrizio
Iop, Aldo
Zaniboni, Alberto
[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 371 - 375
[9] SENP1 participates in Irinotecan resistance in human colon cancer cells
Chen, Ming-Cheng
Nhan, Do Chi
Hsu, Chiung-Hung
Wang, Tso-Fu
Li, Chi-Cheng
Ho, Tsung-Jung
Mahalakshmi, B.
Chen, Mei-Chih
Yang, Liang-Yo
Huang, Chih-Yang
[J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2021, 122 (10) : 1277 - 1294
[10] Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies
Chinn, Danielle C.
Holland, William S.
Mack, Philip C.
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (07) : 1137 - 1149

← 1 2 3 4 5 →